- Home
- NRIX vs TARS Comparison
NRIX vs TARS Comparison
Compare NRIX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | TARS |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRIX | TARS |
|---|---|---|
| Price | $25.57 | $78.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $30.50 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.0M | 673.2K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | $76,987,000.00 | ★ $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | $48.05 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 99.31 | ★ 146.71 |
| 52 Week Low | $8.20 | $53.89 |
| 52 Week High | $28.23 | $91.53 |
Technical Indicators
Market Signals| Indicator | NRIX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 53.24 |
| Support Level | $24.95 | $77.14 |
| Resistance Level | $28.23 | $79.10 |
| Average True Range (ATR) | 1.02 | 3.68 |
| MACD | -0.15 | -0.94 |
| Stochastic Oscillator | 48.20 | 22.37 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.